INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces nine pieces of data, including oral symposia, will be presented at AD/PD™ 2022 - International Conference on Alzheimer’s and Parkinson’s diseases.
March 15, 2022
· 5 min read